Xiaomi Shares Jump on Europe EV Expansion Plan 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Anthropic IPO Marketing Expected to Start in Mid-October 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Add as a preferred source on Google
EAST RUTHERFORD, N.J., Feb. 15, 2018 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will participate in a fireside chat at the 2018 RBC Capital Markets Global Healthcare Conference on February 22, 2018 at 3:05 p.m. EST in New York City.
The live audio webcast and slide presentation can be accessed from the Cambrex website at www.cambrex.com in the Investors section under “Webcasts & Presentations”, and a replay will be available for 90 days after the live event concludes.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact:
Stephanie LaFiura
IR Associate
Tel: +201 804 3037
Email: [email protected]
